HemCon Implements BBCS Software for Clinical Trials

Share Article

Blood Bank Computer Systems, Inc. (BBCS) announced that HemCon Medical Technologies Inc. (HemCon) is their first client to implement the recently distributed BBCS Primary Application 5.4 software (BBCS 5.4) as of June 27th. HemCon has been in clinical trials since May of 2010 for their unique Lyophilized (i.e. freeze-dried) Plasma (LyP) product and uses BBCS software for inventory management and tracking of this product.

Blood Bank Computer Systems, Inc. (BBCS) announced that HemCon Medical Technologies Inc. (HemCon) is their first client to implement the recently distributed BBCS Primary Application 5.4 software (BBCS 5.4) as of June 27th. HemCon has been in clinical trials since May of 2010 for their unique Lyophilized (i.e. freeze-dried) Plasma (LyP) product and uses BBCS software for inventory management and tracking of this product.

“HemCon was able to adapt BBCS software to provide the utility we need at this stage of our clinical trial development and create the foundation for a subsequent FDA licensed product, providing 100% traceability for our single donor, lyophilized plasma,” said HemCon’s Senior Vice President of Research and Development, Lisa Buckley.

The completion of HemCon’s BBCS 5.4 implementation is especially exciting because it is BBCS’ first client to implement this release of the software, including features that are critical to HemCon’s next phase of trials and testing, during which approximately 100 patients will receive LyP transfusions. The entire process of managing and monitoring this new product will be done through the use of the BBCS 5.4 software. The enhanced testing functionality that comes with the BBCS 5.4 software was not only crucial in supporting HemCon’s testing requirements but it will also provide all other BBCS clients the same benefits when testing is needed.

In May of 2008, the U.S. Army selected HemCon, in Portland Oregon, as the recipient of a sole source award to develop, test and secure FDA clearance for the LyP product and delivery system. The $33.5 million, multi-year cooperative agreement is supporting the research and development of the new process. In December of 2008, HemCon selected BBCS as their Blood Establishment Computer System (BECS) to follow FDA’s guidelines for clearance. In 2010, HemCon began their Phase 1 Safety Clinical Trial using autologous LyP. This trial involved transfusing the freeze-dried plasma back to the same person who donated it and was complete in June of 2011. To support their needs, HemCon collaborates with Puget Sound Blood Center in Seattle, Washington, another BBCS client since 1993.

Donors and users alike will benefit from the new features in the BBCS 5.4 release. Blood Center staff will notice enhanced comment posting, access and review which will result in a faster donation process for both parties. The donor also has an improved donation experience with an updated user interface for self-registration and questionnaire processing through the added picture and audio integration. Nearly a third of BBCS clients are currently in the process of implementing the BBCS 5.4 release to provide these new features to their donors and staff.

“As the blood banking industry changes and evolves, our software must do the same. HemCon chose our system because it was built with this in mind; in a way that allows the product to be used for purposes other than standard blood collection,” said BBCS President and CEO, Beth Simon. “We are thrilled to provide HemCon with software solutions during their clinical trials and beyond. They have been able to successfully configure our software for use throughout their testing and manufacturing process, which has paved the way for expansion into new markets. We couldn’t be more excited about this partnership.”

BBCS congratulates HemCon on the successful implementation of the BBCS 5.4 release and looks forward to supporting them through the completion of clinical trials and future projects.

About BBCS

Independently owned and headquartered in the Pacific Northwest, Blood Bank Computer Systems, Inc. (BBCS) has been one of the blood banking industry’s complete software solutions for information and risk management since 1987. BBCS provides comprehensive, rules-based, data management systems that specialize in providing secure, flexible and quality risk management for blood establishments. BBCS works closely with their dynamic client group and partners to continually improve the product line and provided services. The configurability and scalability of BBCS’ software allows for use in a multitude of environments including community and hospital blood bank facilities as well as transfusion, testing and research facilities of all sizes in 19 different states. Overall, BBCS supports over 1.4 million units annually and the largest centralized cross match lab in the USA. To learn more about BBCS, Inc. please visit http://www.bbcsinc.com.

About HemCon Medical Technologies Inc.

HemCon Medical Technologies Inc. founded in 2001, develops, manufactures, and markets innovative technologies for rapid delivery of plasma and hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where rapid supply of plasma and control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic. For more information, please visit http://www.hemcon.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website